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Abstract
Objective—Metaplastic lineages in the oxyntic mucosa of the stomach are critical preneoplastic
precursors of gastric cancer. Recent studies have demonstrated that Spasmolytic polypeptide-
expressing metaplasia (SPEM) in the mouse oxyntic mucosa arises from transdifferentiation of
mature gastric chief cells. Other investigations of intestinal progenitor cells have shown that cells
demonstrating transcriptional activity for Lgr5 in the intestine, colon and gastric antrum function
as adult stem cells. We have now investigated whether cells demonstrating Lgr5 transcriptional
activity in the oxyntic mucosa of mice might be responsible for development of metaplasia.
Design—Lgr5-EGFP-IRES-CreERT2/+;Rosa26R mice were utilized to examine the distribution of
Lgr5 transcriptionally active cells in the normal oxyntic mucosa as well as after treatment with
DMP-777 or L635 to induce acute SPEM. Lineage mapping was performed to determine if LGR5-
expressing cells gave rise to SPEM.
Results—Cells expressing transcriptional activity for Lgr5 in the oxyntic mucosa were present as
scattered rare cells only along the lesser curvature of the stomach. These cells also stained for
markers of chief cells (intrinsic factor and pepsinogen) but never showed any staining for
proliferative markers (Ki-67). In Lgr5-EGFP-IRES-CreERT2/+;Rosa26R mice induced with
tamoxifen, treatment with either DMP-777 or L-635 to induce acute oxyntic atrophy caused
induction of SPEM, but no lineage mapping into SPEM from Lgr5-expressing cells was observed.
Conclusion—The results indicate that, while chief cells with Lgr5-transcriptional activity are
present along the lesser curvature of the gastric oxyntic mucosa, they are not responsible for
production of metaplasia.
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INTRODUCTION
In the normal acid-secreting (oxyntic) gastric mucosa, cell lineages are derived through
orderly differentiation from progenitor cells located in the neck region of gastric glands.
Committed progenitor cells give rise to either short-lived surface cells or long-lived cells of
the gastric gland including gastric parietal cell, mucous neck cells and zymogen-secreting
chief cells.[1, 2] In particular, as mucous neck cells migrate towards the bases of oxyntic
glands they undergo redifferentiation into chief cells without undergoing any intervening
cell divisions.[1, 3] Thus, in the oxyntic glands, proliferating cells are confined to the upper
third of the glands.[4] This pattern contrasts with the organization of the gastric antrum as
well as the intestinal crypts, where proliferative cells are located nearer the bases of antral
glands and intestinal crypts. Recent studies have noted that cells expressing Lgr5 in the
antrum and the intestines can give rise to all of the lineages of these mucosal units,
suggesting that Lgr5 cells represent a critical pluripotent progenitor population.[5, 6, 7, 8] In
contrast, cells with Lgr5 transcriptional activity were rare in the oxyntic regions of the
stomach and only rarely showed any mapping as progenitors of oxyntic mucosal lineages.[5]
Gastric neoplasia is thought to arise in the setting of pre-neoplastic metaplastic cell lineages.
[9] Metaplasia develops in the human stomach following the loss of gastric acid-secreting
parietal cells (oxyntic atrophy), usually in concert with chronic infection with Helicobacter
pylori.[10] In humans, oxyntic atrophy is associated with two types of metaplastic mucous
cell lineages: intestinal metaplasia, which resembles intestinal goblet cells,[11] and
Spasmolytic Polypeptide Expressing Metaplasia (SPEM), which is phenotypically similar to
the deep antral gland cells[12]. In models of acute and chronic induced oxyntic atrophy in
mice, only SPEM is observed.[13, 14, 15] While the origin of these metaplastic lesions has
been uncertain, recent investigations have demonstrated that, in mice, SPEM is derived from
transdifferentiation of mature chief cells into the mucous cell metaplasia.[16, 17] This
transdifferentiation causes the recrudescence of proliferative activity in post-mitotic chief
cells, which is further augmented in the presence of inflammatory infiltrates.[16]
Given the position of cells with Lgr5 transcriptional activity in the bases of some oxyntic
glands, we have sought to determine whether these Lgr5-expressing cells may contribute to
the induction of metaplasia in the setting of acute oxyntic atrophy. While we have
determined that the cells with Lgr5-transcriptional activity in the oxyntic mucosa are
phenotypic chief cells, lineage mapping studies indicate that these cells do not contribute to
SPEM. The results therefore indicate the transdifferentiation of chief cells into SPEM is not
driven by Lgr5-expressing progenitor cells.
MATERIALS AND METHODS
Mice
Eight to ten week old mice were used for all studies. Generation of Lgr5-EGFP-IRES-
CreERT2/+ and Rosa26RLacZ mice has been described previously.[5] Lgr5-EGFP-IRES-
CreERT2/+ mice were generated by standard embryonic stem cell targeting in which EGFP
was knocked into the Lgr5 coding region along with an internal ribosome re-entry site
(IRES) followed by CreERT2. Cre recombinase was activated in Lgr5-EGFP-IRES-
CreERT2/+/Rosa26RLacZ mice by intraperitoneal injection of tamoxifen (1 mg/0.1 ml corn
oil) for 4 doses every other day. During the experiments, the mice were maintained with
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regular mouse chow and water ad libitum in a temperature-controlled room under a 12-hour
light/dark cycle. The care, maintenance, and treatment of animals in these studies followed
protocols approved by the Institutional Animal Care and Use Committee of Vanderbilt
University.
Drugs
Preparation and treatment of the DMP-777 have been described previously.[18] L-635 was a
gift of Merck & CO., Inc (Rahway, NJ). Mice were administered L-635 orally as a gavage
(350 mg/kg) once daily for 3 days.
β-galactosidase analysis
Assessment of β-galactosidase activity was used to examine the efficiency of recombination
at the Rosa26RLacZ reporter allele after induction of Cre activity. Stomach whole-mounts
were prepared, fixed and exposed to 5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside (X-
gal) substrate using a method previously reported.[19] The stomachs were opened along the
greater curvature and washed with ice-cold fixative containing 1% formaldehyde, 0.2%
glutaraldehyde and 0.02% Nonidet P-40 (NP40) in PBS (Ca+ and Mg+ free). The stomachs
were immediately incubated for 2 h in a 20-fold volume of ice-cold fixative at 4 °C on a
rolling platform. The fixative was removed and the tissues washed twice in PBS for 20 min
at room temperature (20 °C) on a rolling platform. The β-galactosidase substrate (5 mM
K3Fe(CN)6, 5 mM K4Fe(CN)6·3H2O, 2 mM MgCl2, 0.02% NP40, 0.1% sodium
deoxycholate and 1 mg/ml X-gal in PBS) was then added and the tissues incubated in the
dark overnight at room temperature. The substrate was removed and the tissues washed
twice in PBS for 20 min at room temperature on a rolling platform. The tissues were then
fixed overnight in a 20-fold volume of 4% paraformaldehyde in PBS at 4 °C in the dark on a
rolling platform. The paraformaldehyde was removed and the tissues washed twice in PBS
for 20 min at room temperature on a rolling platform. The stained tissues were transferred to
tissue cassettes and paraffin blocks prepared using standard methods. Tissue sections were
prepared and counterstained with nuclear fast red (Vector Laboratories, Burlingame, CA).
The number of X-gal positive cells was analyzed in all strips of each stomach. Using an
Ariol SL-50 slide scanner imaging system (Genetix, San Jose, CA; Vanderbilt Epithelial
Biology Center Shared Resource) and light microscopy (200 ×), a mucosal length of 26,000
µm was analyzed to determine positive cells in the oxyntic mucosa.
Immunohistochemistry
For immunohistochemistry deparaffinized sections were rehydrated, and antigens were
retrieved using Target Retrieval solution (Dako, Carpinteria, CA) in a pressure cooker for 15
minutes followed by standard detection with 3,3-diaminobenzidine (DAB) or alkaline
phosphatase using a kit from Vector Laboratories. Samples were counter-stained with
hematoxylin. In some cases, secondary antibodies were conjugated to AlexaFluor 488
(Invitrogen, Camarillo, CA) or Cy-3 and nuclei were counterstained with 4,6-diamidino-2-
phenylindole (DAPI). We used the following primary antibodies : mouse anti-TFF2 (1:100,
a gift from Dr Nicholas Wright, Cancer UK, London, England), mouse anti-H+/K+-ATPase
(1:2000, a gift from of Dr Adam Smolka, Medical University of South Carolina, Charleston,
SC), rabbit anti-intrinsic factor (1:1000, a gift from Dr David Alpers, Washington
University, St. Louis, MO), rabbit monoclonal anti-GFP (1:500. Cell Signaling, Danvers,
MA), rat IgG anti-Ki-67 (1:50, Dako), sheep IgG anti-pepsinogen II (1:50000 Abcam,
Cambridge, MA). The number of GFP positive cells was analyzed in all strips of each
stomach. Using the Ariol SL-50 slide scanner and light microscopy (200 X), a mucosal
length of 31,000 µm was analyzed to determine immunoreactive positive cells in the oxyntic
glands.
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For immunofluoresence staining of β-galactosidase, deparaffinized sections were sections
were rehydrated, and antigens were retrieved using Target Retrieval solution (Dako) in a
pressure cooker for 30 minutes followed by slow cooling without releasing pressure at room
temperature for 1 hour, and slides were blocked with protein block serum-free (Dako) and
incubated with rabbit anti-β-galactosidase (1:20000, AbD Serotec, Oxford, UK) overnight at
4°C. For double immunofluoresence staining of Mist1 and GFP, sections were incubated
with rabbit anti-Mist1 (1:100,000, a gift from Dr Jason Mills, Washington University, St.
Louis, MO) overnight at 4°C. Biotinylated secondary antibodies were visualized using
streptavidin-conjugated horseradish peroxidase in conjunction with cy3-conjugated
Tyramide Signal Amplification kit (PerkinElmer Life Sciences, Boston, MA). For Mist1
immunostaining, biotinylated secondary antibodies were visualized using streptavidin-
conjugated horseradish peroxidase in conjunction with Fluorescein-conjugated Tyramide
Signal Amplification kit. Sections were mounted using ProLong Gold Antifade Reagent
with 4,6-diamino-2-phenylindole (DAPI) (Invitrogen) was used for nuclear counterstain and
mounting medium.
Statistics
The data were analyzed with the JMP software package (version 4.0; SAS Institute, Cary,
NC). GFP positive cell numbers and X-gal positive cell numbers were compared by analysis
of variance followed by post hoc analysis of significant means by the Dunnett test. For all
comparisons, P values less than 0.05 were considered statistically significant.
RESULTS
We first re-examined the geographic distribution of cells expressing Lgr5 transcriptional
activity in the stomach Lgr5-EGFP-IRES-CreERT2 mice (n=4) that express both tamoxifen-
inducible Cre recombinase and GFP under the control of the Lgr5 promoter. Scattered GFP
staining cells were observed, sometimes as clusters, at the bases of glands on the lesser
curvature of the gastric oxyntic mucosa, but no cells were observed along the greater
curvature of the oxyntic region (Figure 1A, B). In contrast, GFP staining cells were observed
in the bases of antral glands throughout the entire circumference of the antrum (Figure
1C,D).
In the intestine and the gastric antrum, Lgr5 transcript expression marks a population of
proliferative stem cells with the potential to differentiate into all of the cell lineages of the
glands and crypts[5, 19]. However, we did not observe any dividing cells through Ki-67
staining at the bases of oxyntic glands (Supp. Fig. 1). Thus, the position of the Lgr5-
expressing cells in the oxyntic mucosa appeared to indicate a distinct population of cells.
Given the position of the cells in the bases of oxyntic glands, we sought to determine
whether these Lgr5-expressing cells might be chief cells. Figure 2 demonstrates that all of
the Lgr5-expressing cells in the oxyntic mucosa also stained for pepsinogen II and intrinsic
factor. In addition, most of the GFP staining Lgr5-expressing cells stained for Mist1 (data
not shown). The staining of Lgr5-expressing cells with pepsinogen and intrinsic factor
antibodies suggest that these cells are phenotypic chief cells. However, it is notable that
most chief cells on the lesser curvature did not show Lgr5 expression and no chief cells on
the greater curvature showed Lgr5 expression. Thus, Lgr5-transcriptional activity is present
in a sub-population of phenotypic chief cells on the lesser curvature.
We have recently demonstrated that loss of parietal cells leads to induction of metaplasia in
mice through the transdifferentiation of chief cells into SPEM.[16] We therefore sought to
test whether Lgr5-expressing chief cells may contribute to SPEM. In DMP-777 treatment
(n=4), SPEM develops after 14 days of drug treatment in the absence of inflammation,[20]
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while with L-635 SPEM develops after just 3 days of treatment (n=4) in association with a
prominent inflammatory infiltrate.[16] In both acute oxyntic atrophy models, we saw
induction of SPEM (as demonstrated by TFF2-expressing cells at the bases of gastric
glands)(Figure 3) with a concomitant reduction in the numbers of GFP staining cells at the
bases of oxyntic glands (Figure 4). However, no significant changes in the numbers or
distribution of Lgr5-expressing, GFP-staining cells were observed in the antrum in either
model (Supp. Figure 2). Similar results were obtained when sections were stained with
immunohistochemistry for GFP (Figure4).
We next sought to examine whether cells with Lgr5 transcriptional activity give rise to
SPEM following induction of acute oxyntic atrophy using in vivo lineage tracing. Lgr5-
EGFP-IRES-CreERT2/+;Rosa26RLacZ mice were treated with four doses of tamoxifen and
following 10 days without treatment were subsequently treated with either 14 days of
DMP-777 (n=5) or 3 days of L-635 (n=5). Figure 5 demonstrates that isolated blue X-gal
stained β-galactosidase-expressing cells were observed in the bases of oxyntic glands along
the lesser curvature, indicative of cells with Lgr5 transcriptional activity. While both
DMP-777 and L-635 treatments led to induction of SPEM, we did not observe any X-gal
staining in these cells, so they were not derived from previously labeled Lgr5-expressing
cells (Figure 5). In contrast, the entire epithelium of multiple antral gastric units was
clonally X-gal positive, confirming that Lgr5 positive cells at the base of the antral glands
were multipotent stem cells responsible for maintaining epithelial renewal under normal
homeostatic conditions as well as oxyntic atrophy (Figure 5). We confirmed the presence of
Lgr5 positive stem cell in this region by X-gal staining as well as immunohistochemistry
against β-galactosidase protein (Figure 6). These findings indicate that SPEM was not
derived from cells with Lgr5 transcriptional activity.
DISCUSSION
Oxyntic atrophy, the loss of parietal cells in the gastric oxyntic mucosa, is requisite for the
development of preneoplastic metaplasias.[21] Indeed, in humans oxyntic atrophy is the
strongest correlate with risk for gastric cancer.[22] While the association of metaplasia in
the stomach with the development of gastric cancer was first proposed over 20 years ago,
[11] the origin of metaplasia has been controversial. Recent investigations have established
that SPEM lineages in mice are predominantly derived from transdifferentiation of mature
chief cells, especially in the presence of significant inflammatory infiltrates as observed in
H. felis-infected mice or mice treated with L-635.[16] While those studies demonstrated that
metaplasia derives from endogenous mucosal progenitors, it also indicates that metaplasia
does not evolve from the normal oxyntic mucosal progenitors.[17] Rather, metaplasia
develops from transdifferentiation of mature chief cells and recrudescence of proliferative
capacity in the presence of inflammatory infiltrates.
In the intestine, crypt base cells that express Lgr5 can give rise to all of the normal lineages
of the intestinal crypt and villus structures and can also give rise to neoplastic lineages.[19]
Similarly, Lgr5-expressing cells also exist in the gastric antrum that can give rise to antral
glandular lineages.[5] In contrast, few Lgr5-expressing cells exist in the oxyntic mucosa and
those are located exclusively along the lesser curvature in mice. The results presented here
indicate that the oxyntic mucosal cells with Lgr5 transcriptional activity are phenotypic
chief cells, which express both intrinsic factor and pepsinogen. Nevertheless, following
treatment with either oxyntic atrophy-inducing drug, we failed to observe any evidence for
lineage mapping of the cells with Lgr5 transcriptional activity into SPEM lineages. Thus, in
this case, cells with Lgr5 transcriptional activity in the gastric oxyntic mucosa do not
represent progenitors for metaplasia. Indeed, in contrast with the Lgr5-expressing cells in
the intestinal crypts and antral glands, we have found no evidence for proliferative capacity
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(as indicated by staining with Ki-67) in any Lgr5-expressing cells in the oxyntic mucosa in
either untreated or treated mice.
The significance of Lgr5-transcriptional activity in a small population of cells along the
lesser curvature of the stomach remains unclear. Since there presently is no antibody that
can reliably detect Lgr5 immunostaining in mice, we cannot assess at this time whether
these cells are actually making Lgr5 protein. Thus, the transcripts may be made in these cells
without translation. In addition, it is important to note that, while Lgr5-expressing cells in
the antrum and the intestines also show proliferative marker staining, no Ki-67 staining is
ever seen in the chief cells of the normal stomach. Previous investigations have
demonstrated that Olfactomedin 4 (OLFM4) co-labels Lgr5-expressing cells in the
intestine[23]. However, we have previously reported that OLFM4 expression is markedly
increased in SPEM and intestinal metaplasia in the human stomach[24]. Nevertheless, none
of our studies have found up-regulation of Lgr5 expression in metaplasia either in humans or
mice[18, 24, 25]. All of these results indicate that expression of lineage markers may vary
both between gastrointestinal tissues and among pathological lineages.
While our recent studies on the origin of SPEM have indicated that SPEM originates from
mature Mist1-expressing chief cell lineages,[5] it remains unclear whether chief cells, as a
general population, can transdifferentiate into SPEM or whether SPEM arises from a subset
of chief cells. Interestingly, the present data identify a population of chief cells on the lesser
curvature with Lgr5 transcriptional activity, which do not appear to have the capacity to
transdifferentiate into SPEM. The data therefore do indicate that subpopulations of chief
cells with differing capacities for transdifferentiation do exist. More importantly, however,
the results support the concept that SPEM may arise from a general capacity of many chief
cells to transdifferentiate into mucous cell metaplasia.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SUMMARY BOX
What is already known about this subject:
• In humans, intestinal metaplasia and spasmolytic polypeptide-expressing
metaplasia (SPEM) are associated with the development of gastric cancer.
• Acute or chronic loss of parietal cells in mouse leads to the emergence of SPEM
through transdifferentiation of chief cells into mucous cell metaplasia.
• Lgr5-expressing cells in the intestine and gastric antrum are cycling pluripotent
progenitor cells that can give rise to all lineages in the mucosa.
What are the new findings:
• A small number of cells with Lgr5 transcriptional activity are present in the
lesser curvature of oxyntic mucosa of the mouse stomach and these cells are
phenotypic chief cells.
• Induction of acute parietal cell loss with either DMP-777 or L635 leads to
induction of SPEM but none of the mucous cell metaplasia is derived from
Lgr5-expresing cells.
• Lgr5-transcriptionally active cells are not pluripotent progenitor cells in the
gastric acid-secreting mucosa and SPEM is not derived from Lgr5 expressing
cells.
How might it impact on clinical practice in the foreseeable future?
• Identification of SPEM may be a critical early biomarker for risk of gastric
cancer.
Nam et al. Page 9
Gut. Author manuscript; available in PMC 2013 September 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Cells with Lgr5 transcriptional activity in the mouse stomach
Stomachs from Lgr5-EGFP-IRES-CreERT2/+ mice were immunostained for GFP expression.
A. Circumferential section of the gastric oxyntic region shows GFP immunostaining cells at
the bases of glands only on the lesser curvature. Bar size=700 µm. B. Higher magnification
of GFP-staining cells along the lesser curvature of the oxyntic region. Note no GFP-staining
cells along the greater curvature of the gastric oxyntic region. Bar size=100 µm. C.
Circumferential section of the antrum stained for GFP shows stained cells at the bases of
glands throughout the antrum. Bar size=100 µm. D. Higher magnification of GFP-staining
cells in the antrum. Bar size=100 µm.
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Figure 2. Cells with Lgr5 transcriptional activity in the oxyntic mucosa are phenotypic chief cells
Sections of stomach from Lgr5-EGFP-IRES-CreERT2/+ mice were dual immunostained for
either (A) GFP and pepsinogen II, (B) GFP and intrinsic factor or (C) GFP and Mist1. The
immunostaining shows that the GFP-expressing cells all also labeled with pepsinogen,
intrinsic factor and Mist1. Bar size=50 µm.
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Figure 3. Induction of SPEM in treatment of Lgr5-EGFP-IRES-CreERT2/+ mice with DMP-777
or L635
Sections of the gastric oxyntic region from untreated mice, mice treated with DMP-777 for
14 days or mice treated with L635 for 3 days were dual immunostained for GFP and TFF2.
Dual labeling overlays of GFP and TFF2 staining are shown in the third column. Triple
labeling overlays with GFP, TFF2 and DAPI are shown in the fourth column. The staining
demonstrates that treatment with either drug led to a decrease in immunostaining for GFP.
Also none of the GFP staining cells stained for TFF2 in the untreated stomach or in sections
with SPEM. Bar size=50 µm.
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Figure 4. GFP immunohistochemical staining in oxyntic region and antrum
GFP staining of cells expressing Lgr5 transcriptional activity in sections of oxyntic and
antral mucosa was performed using peroxidase-labeled secondary antibodies and DAB
chromagen. Sections of oxyntic mucosa and antrum were stained from untreated Lgr5-
EGFP-IRES-CreERT2/+ mice and Lgr5-EGFP-IRES-CreERT2/+ mice treated with either
DMP-777 for 14 days or L-635 for three days. The quantitation of GFP positive cells in
sections from the oxyntic mucosa is shown at the bottom (*p<0.01 compared with untreated
mice). Bar size=100 µm.
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Figure 5. Lgr5-transcriptional activity does not map into SPEM
Lgr5-EGFP-IRES-CreERT2/+; Rosa26RLacZ mice were treated with 4 doses of tamoxifen and
then following a 10 day hiatus mice were either maintained without further treatment,
treated with 14 days of DMP-777 or treated with 3 days of L-635. At sacrifice, stomachs
were fixed in glutaraldehyde and then incubated with X-gal as whole mounts. The sections
demonstrate that only scattered cells were observed at the bases of oxyntic glands even after
treatment and no X-gal staining was observed in SPEM. In antrum, multiple clonal X-gal-
positive antral glandular lineages were visible in untreated Lgr5-EGFP-IRES-CreERT2/+
mice and Lgr5-EGFP-IRES-CreERT2/+ mice treated with either DMP-777 for 14 days or
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L-635 for three days. The quantitation of X-gal positive cells in sections from the oxyntic
mucosa is shown at the bottom (*p<0.01 compared with untreated mice). Bar size=100µm
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Figure 6. Bacterial β-galactosidase immunohistochemical staining in the oxyntic mucosa and
antrum of Lgr5-EGFP-IRES-CreERT2/+ mice
Lgr5-EGFP-IRES-CreERT2/+; Rosa26RLacZ mice were treated with 4 doses of tamoxifen and
then following a 10 day hiatus mice were either maintained without further treatment,
treated with 14 days of DMP-777 or treated with 3 days of L-635. The sections demonstrate
that only scattered β-galactosidase (red) positive cells were observed at the bases of oxyntic
glands even after treatment and no β-galactosidase staining was observed in SPEM.
However, β-galactosidase (red) positive antral glandular lineages were visible in untreated
Lgr5-EGFP-IRES-CreERT2/+ mice and Lgr5-EGFP-IRES-CreERT2/+ mice treated with either
DMP-777 for 14 days or L-635 for three days. Bar size=50µm
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